Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

Slides:

Advertisements

Similar presentations

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Advertisements

Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome

Addressing the Challenges in Primary and Secondary Stroke Prevention

HOPE: Heart Outcomes Prevention Evaluation study

Pravastatin in Elderly Individuals at Risk of Vascular Disease

The Anglo Scandinavian Cardiac Outcomes Trial

Selection of NSAIDs for Osteoarthritis

PCSK9 Inhibitors Post-CVOTs

Statin Selection in the Elderly

Optimizing Statin Therapy

An Endocrinology Clinic in Dyslipidemia

Statin Selection Aimed to Reduce New-Onset DM Risk:

Omega-3 Prescriptions vs Supplements in Practice

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Challenging Statin Intolerance: Back to Basics

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Select Topics in Cardiovascular Medicine

Obesity and Dyslipidemia: How Would You Treat?

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Statins and the Elderly Patient

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

TNT Study: Baseline Characteristics of the Patients

The Hypertension in the Very Elderly Trial (HYVET)

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Statin Class in Session

Diabetes Increases Risk of CVD

Assessing the State of Statin Therapy

An Update on PCSK9 Inhibitors

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

Evaluating LDL-C Recommendations

Statins and Glucose Metabolism: Are All Agents Alike?

Statin Class in Session

Personalizing Statin Therapy in Patients With HIV

A Journal Club on Lipid Management:

PCSK9 Inhibitors and Cardiovascular Outcomes

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Improving Appropriate Access to PCSK9 Inhibitors

Statins and HIV:.

New LDL-C Lipid Targets

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Exploring Statin Intolerance

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

Lipid Clinic Challenge

Aspirin and Cardioprevention in 2018

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Residual CV Risk in Patients With Dyslipidemia and Stable CAD

Statins, Obesity, and Hyperlipidemia

Glucose Management and Statin Therapy

How to Optimize Cholesterol Management in High-Risk CV Patients

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Potential mechanisms whereby statins may reduce the risk of stroke

Factor Xa Inhibitors in Coronary Artery Disease

New Lipid-Lowering Guidelines

HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.

Lipid Updates From Spring 2019

An Update on PCSK9 Inhibitors

Glucose Management and Statin Therapy

Omega-3s vs Pure EPA in Clinical Practice

Updates on Dyslipidemia

Lipids, the Heart, and the Kidney

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

PCSK9 Inhibitors and Real-World Evidence

Shared-Decision Making in Dyslipidemia

Presentation transcript:

Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

Definition of Elderly

The Elderly and Vascular Disease

Tailoring Lipid-Lowering Therapy in the Elderly

Statins Highly Favorable Risk-Benefit Ratio

Highest Risk of Statin Toxicity

Polypharmacy and Drug-Drug Interactions

Statin Pharmacokinetics

Pitavastatin and Pravastatin: Less Likely to Interact With Common Medications in CV Care

Common Drug Interactions With Statins

PROSPER Study Design

PROSPER Primary Endpoint

Primary Prevention in the Elderly MI and Stroke Reduced With Statins

JUPITER and HOPE-3 Trials

STAREE STAtins for Reducing Events in the Elderly

Secondary Prevention

Secondary Prevention (cont)

CTT Meta-Analysis

Guideline Recommendations Statin Therapy in the Elderly (>75 Years)

SCORE Cardiovascular Disease Risk Estimation

REAL-CAD: Primary Endpoint CV Death/MI/Ischemic Stroke/Unstable Angina

Nonadherence Is a Risk Factor for CV Events

Reassuring the Patient About Statins

2015 ACC Health Policy Statement Team Management

Conclusion

Abbreviations

Abbreviations (cont)